WEST BRIDGEWATER, Mass., Nov. 12 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that total revenue for the three months ended September 30, 2007 was $138,052 compared to $92,211 for the same period in 2006, an increase of approximately 50%. Revenue from the sale of PCT products and services was $106,787 for the quarter as compared to $92,211 for the same period in the prior year. This increase in revenue from PCT products and services was primarily the result of a record number of installations of the Company's PCT Sample Preparation System ("PCT System") -- the total number of PCT Systems installed during the quarter was eight as compared to three in the same period in 2006. Also contributing to this increase in revenue was an increase in the number of PULSE Tubes sold, revenue from PCT Systems under lease, and the recognition of extended service contract revenue. The Company also recorded $31,265 of grant revenue during the third quarter of 2007. During the same period in 2006, no grant revenue was recorded.
The Company reported total revenue of $471,799 for the nine months ended September 30, 2007 as compared to $174,409 for the nine months ended September 30, 2006, an increase of approximately 171%. Revenue from the sale of PCT products and services was $281,084 for the nine months ended September 30, 2007 as compared to $174,409 for the same period in the prior year. This increase in revenue from PCT products and services was primarily the result of a total of thirteen installations of PCT Systems (sale of eleven and the lease of two) in the first nine months of 2007 versus five in the first nine months of 2006. Also contributing to this increase in revenue was a significant increase in the number of PULSE Tubes sold, revenue from PCT Systems under lease, and the recognition of extended service contract revenue. The Company also recorded $190,715 of grant revenue during the first nine months of 2007. During the same period in 2006, no grant revenue was recorded.
Net loss for the quarter ended September 30, 2007 was $(1,095,978) or $(0.53) per share, basic and diluted, compared to a net loss of $(630,539) or $(0.26) per share, basic and diluted, for the same period in 2006. Net loss for the nine months ended September 30, 2007 was $(183,145) or $(0.09) per share, basic and diluted, compared to a net loss of $(1,754,834) or $(0.72) per share, basic and diluted, for the same nine month period in 2006. This significant reduction in net loss was due entirely to the gain of approximately $2,000,000 from the sale of our remaining shares of Panacos Pharmaceuticals common stock and from the recognition of an approximately $1,156,000 gain on the sale of net assets related to discontinued operations of Source Scientific, LLC. As of September 30, 2007, the Company had cash and cash equivalents of approximately $6.0 million, as compared to approximately $5.3 million on December 31, 2006.
Edward H. Myles, Senior Vice President of Finance and CFO commented: "During the third quarter of 2007, we carefully deployed our capital resources towards the continued development and commercialization of PCT. To this end, our cash burn and operating loss were in line with our internal expectations as we continued to make progress building market awareness while concomitantly driving the installed base of instruments."
Mr. Myles continued: "We are quite pleased that we installed eight PCT Systems during the third quarter, more than double the number that we installed in the prior year period. Although total revenue increased significantly, revenue from PCT products and services did not grow at the same rate for three primary reasons: (1) four of eight PCT Systems sold used the Barocycler NEP2320 instrument from the initial prototype run of this unit -- these PCT Systems have a list price of approximately half of the Barocycler NEP3229-based PCT Sample Preparation System; (2) we accepted the return, and issued a credit, for the full price (approximately $30,000) of a Barocycler NEP3229 PCT System that was sold last year because the sample throughput did not ultimately meet the needs of that particular researcher; and (3) two of the eight installations in the quarter were completed under lease/rental agreements rather than sales, whereby revenue will be recorded over the life of the specific agreement."
Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, Inc. said: "We are very pleased with the significant increase in the number of PCT Systems installed during the first nine months of 2007, as compared to the same period in 2006. This increase gives us reason for continued optimism since it was achieved with just two sales people for the nine month period and with very limited availability of the new NEP2320 instrument (units sold were from an initial prototype run of eleven instruments, which were expected to be used exclusively for demonstration and collaboration purposes). Furthermore, we believe that our business plan is beginning to be validated, as growth in our installed base of PCT Systems has begun to result in the realization of recurring revenue -- such as PULSE Tube sales and extended service contracts."
Mr. Schumacher continued: "There were a number of additional achievements during the third quarter, including: (1) the hiring of four additional sales directors (and one more in Q4), bringing our total number on staff to seven seasoned, technical sales directors; (2) presentations and publications by several independent, eminent scientists describing their successful use of PCT in the areas of agriculture, microbiology, and human disease; (3) confirmation of the use of the NEP2320 PCT System as a highly successful demonstration tool for our sales team; and (4) continued expansion of our successful collaboration programs with existing and new researchers throughout the US."
Mr. Schumacher concluded: "We continue to believe that we have developed the 'best-in-class' sample preparation system available today, one that we believe offers significant advantages in a number of key areas -- including safety, speed, versatility, reproducibility, and quality -- to the estimated 390,000 scientists worldwide who extract DNA, RNA, proteins, and small molecules in their research studies. Combined with a new sales team of seven ambitious and experienced personnel, strong collaborations, and emerging market penetration, we believe that we are well poised to finish the year strong and to enter 2008 with our resources squarely focused on continuing and expanding our commercialization efforts."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.
Financial Teleconference and Web-cast
As announced on November 8, 2007, the Company will host a teleconference at 4:30 pm EST on Monday November 12, 2007 to discuss its third quarter financial results and to provide a business update.
Forward Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the Company's expectations for the remainder of 2007 and 2008, including the continued expansion of the Company's commercialization efforts, the anticipated quality and benefits of the Company's products, and the potential use of PCT in agriculture, microbiology, and human disease; beliefs regarding the validation of the Company's business plan due to Company's growing installed base of PCT Systems; and the Company's estimate of the number of scientists extracting DNA, RNA, proteins, and small molecules. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT Sample Preparation System; the Company's financial results for the three and nine months ended September 30, 2007 may not necessarily be indicative of future results as future revenues may not meet expectations due to the possible failure of the Company's products to achieve commercial acceptance, changes in customers needs and technological innovations, and expenses that may be higher than anticipated due to unforeseen cost increases; if the Company's expenses are higher than anticipated or if the Company's revenues do not increase, the Company may not have sufficient cash to support its planned activities and the Company may be unable to obtain financing on acceptable terms; the Company's new external sales force may not be successful in selling the Company's PCT product line; and the Company may be unable to develop new PCT-related products that achieve commercial acceptance or the status of "best-in-class" sample preparation method. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward- looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
Consolidated Balance Sheets (Unaudited)
September 30, December 31,
ASSETS 2007 2006
Cash and cash equivalents $6,005,462 $5,335,282
Accounts receivable 75,142 37,495
Inventories 238,109 19,658
Prepaid income taxes 56,863 38,687
Income tax receivable 23,494 710,013
Prepaid expenses, deposits, and other
current assets 583,418 246,776
Investments in marketable securities - 2,060,875
Total current assets 6,982,488 8,448,786
PROPERTY AND EQUIPMENT, NET 233,773 207,696
Intangible assets, net 340,448 376,922
Assets of discontinued operation - 1,420,996
Total other assets 340,448 1,797,918
TOTAL ASSETS $7,556,709 $10,454,400
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable $260,859 $174,289
Accrued employee compensation 280,717 242,497
Other accrued expenses 143,528 150,978
Income taxes payable 43,339 45,962
Deferred taxes - 669,520
Deferred revenue 20,814 4,099
Total current liabilities 749,257 1,287,345
LONG TERM LIABILITIES
Deferred revenue 7,568 9,126
Liabilities of discontinued operation - 1,042,493
Total long term liabilities 7,568 1,051,619
TOTAL LIABILITIES 756,825 2,338,964
Common stock, $.01 par value;
20,000,000 shares authorized;
2,065,425 shares issued and
outstanding 20,654 20,654
Additional paid-in capital 5,600,110 5,347,641
Accumulated other comprehensive income - 1,384,876
Retained earnings 1,179,120 1,362,265
Total stockholders' equity 6,799,884 8,115,436
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY $7,556,709 $10,454,400
Consolidated Statements of Operations
For the Three Months For the Nine Months
September 30, September 30,
2007 2006 2007 2006
PCT products, services,
other $106,787 $92,211 $281,084 $174,409
Grant revenue 31,26 - 190,715 -
Total revenue 138,052 92,211 471,799 174,409
COSTS AND EXPENSES:
Cost of PCT products and
services 42,276 90,037 131,558 188,688
Research and development 519,303 324,525 1,518,851 984,844
Selling and marketing 379,448 127,419 986,801 322,803
General and administrative 578,238 380,065 1,683,782 1,665,172
Total operating costs and
expenses 1,519,265 922,046 4,320,992 3,161,507
Operating loss from
continuing operations (1,381,213) (829,835) (3,849,193) (2,987,098)
Realized gain on securities
available for sale - - 2,028,720 517,938
Interest income 75,732 88,190 227,816 305,982
Total other income 75,732 88,190 2,256,536 823,920
Loss from continuing
operations before income
taxes (1,305,481) (741,645) (1,592,657) (2,163,178)
Income tax benefit from
continuing operations 209,503 111,106 253,539 408,344
Loss from continuing
operations (1,095,978) (630,539) (1,339,118) (1,754,834)
Gain on sale of net assets
related to discontinued
operations (net of income
tax of $218,060) - - 1,155,973 -
Net loss $(1,095,978) $(630,539) $(183,145)$(1,754,834)
Loss per share from
- basic and diluted $(0.53) $(0.26) $(0.65) $(0.72)
Income per share from
- basic and diluted - - 0.56 -
Net loss per share
- basic and diluted $(0.53) $(0.26) $(0.09) $(0.72)
Weighted average number of
shares used to calculate
income (loss) per share
- basic 2,065,425 2,422,675 2,065,425 2,424,351
Richard T. Schumacher, President & CEO
Edward H. Myles, Senior Vice President of Finance & CFO
Pressure BioSciences, Inc.
|SOURCE Pressure BioSciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved